Drug Type Small molecule drug |
Synonyms AROG-401, NAX 035, NAX035 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC35H32ClNO4 |
InChIKeyGCLQZWOKRXFXAK-UHFFFAOYSA-M |
CAS Registry1499162-85-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Jan 2025 | |
Colorectal Cancer | Phase 1 | - | 01 Jan 2025 | |
Malignant Pleural Mesothelioma | Phase 1 | - | 01 Jan 2025 | |
Non-Small Cell Lung Cancer | Phase 1 | - | 01 Jan 2025 | |
Ovarian Cancer | Phase 1 | - | 01 Jan 2025 | |
Breast Cancer | Preclinical | United States | 15 Dec 2023 | |
Breast Cancer | Preclinical | Italy | 15 Dec 2023 | |
Breast Cancer | Preclinical | Italy | 15 Dec 2023 | |
Mesothelioma, Malignant | Preclinical | Spain | 12 Oct 2022 | |
Small Cell Lung Cancer | Discovery | Spain | 12 Oct 2022 |